Felix Baker：プロフィール、収入、実績

Felix Baker

Co-founder of Baker Bros. Advisors; biotechnology company director

Felix J. Baker is a biotechnology investor and co-founder of Baker Bros. Advisors. Trained as a scientist at Stanford, he earned a bachelor’s degree in biology in 1991 and a doctorate in immunology in 1998; he also completed two years of medical school. He entered fund management in the 1990s and co-founded Baker Bros. with Julian Baker in 2000. His work includes investment and board service across biotechnology companies, as well as university philanthropy and bioscience research support. Kodiak’s director biography documents his service there from 2015 and his committee responsibilities. The Biotech All-Star Tracker’s use of Baker Bros. filings does not mean that he personally manages or endorses it.

人生の局面1

Felix Bakerの人生の局面ごとに八角形が一つあります。八つの軸はそれぞれ、出典付きの文書化された証拠をもとに、書面の基準表に照らして0から5まで採点します。証拠のない軸は空白であり、0ではありません。合計も理想的な形もありません。これはプロフィールであり、順位付けではありません。外見と人格は、証拠から採点できないため軸にしていません。

Felix Baker

Co-founder of Baker Bros. Advisors; biotechnology company director

人生の局面1

ファンドの保有銘柄

Baker Bros. Advisors — SEC 13F

2026/06/30時点 · 古い時点の情報

提出日 · 2026/08/14

出典 ↗

These are the investment manager’s reported positions, not the named person’s personal brokerage holdings. Form 13F shows reportable long securities at quarter-end and omits cash, short positions and many foreign/private assets. Showing 83 of 83 reported share positions; full filings are linked. 1 option, principal-amount or warrant/debt rows are excluded. Option figures describe underlying exposure, not option premiums. Allocation is within the reported non-option share positions, not total fund assets. 13F does not disclose purchase costs or actual P&L.

Baker Bros. Advisors — SEC 13F · 2026/06/30時点
銘柄	構成比	株数	取得原価	時価	含み損益
CUSIP 45337C102Incyte Corporation — COM	17.54%	30,762,330	非公開	$3,487,217,729.002026/06/30	非公開
CUSIP 07725L102BeOne Medicines Ltd. — SPONSORED ADS	12.61%	8,801,567	非公開	$2,508,182,548.002026/06/30	非公開
CUSIP 76155X100Revolution Medicines, Inc. — COM	10.78%	11,443,357	非公開	$2,143,111,899.002026/06/30	非公開
CUSIP 558868105Madrigal Pharmaceuticals, Inc. — COM	5.79%	2,143,131	非公開	$1,150,754,190.002026/06/30	非公開
CUSIP 004225108ACADIA Pharmaceuticals Inc. — COM	5.46%	42,912,904	非公開	$1,085,696,471.002026/06/30	非公開
CUSIP 501575104Kymera Therapeutics, Inc. — COM	4.99%	8,657,242	非公開	$992,725,940.002026/06/30	非公開
CUSIP 457669307Insmed Incorporated — COM PAR $.01	4.72%	8,796,111	非公開	$937,841,355.002026/06/30	非公開
CUSIP 15102K100Celcuity Inc. — COM	4.16%	7,915,792	非公開	$828,150,159.002026/06/30	非公開
CUSIP 50015M109Kodiak Sciences Inc. — COM	3.9%	19,919,186	非公開	$776,051,487.002026/06/30	非公開
CUSIP 76243J105Rhythm Pharmaceuticals, Inc. — COM	3.13%	5,604,483	非公開	$622,265,747.002026/06/30	非公開
CUSIP 74006W207Praxis Precision Medicines, Inc. — COM	2.95%	1,753,198	非公開	$586,953,158.002026/06/30	非公開
CUSIP G01767105Alkermes plc — SHS	2.64%	10,012,267	非公開	$524,592,729.002026/06/30	非公開
CUSIP 86627T108Summit Therapeutics Inc. — COM	2.4%	32,786,348	非公開	$477,697,090.002026/06/30	非公開
CUSIP 384747101GRAIL, Inc. — COM	1.38%	4,028,614	非公開	$275,033,478.002026/06/30	非公開
CUSIP 00288U106AbCellera Biologics Inc. — COM	1.3%	33,012,138	非公開	$259,145,283.002026/06/30	非公開
CUSIP 45258J102Immunovant, Inc. — COM	1.05%	5,435,220	非公開	$209,419,027.002026/06/30	非公開
CUSIP 45166A102IDEAYA Biosciences, Inc. — COM	0.94%	5,010,030	非公開	$186,723,818.002026/06/30	非公開
CUSIP G52694109Kiniksa Pharmaceuticals International, plc — ORD SHS CL A	0.91%	2,834,643	非公開	$181,275,420.002026/06/30	非公開
CUSIP G76279101Roivant Sciences Ltd. — SHS	0.84%	4,716,831	非公開	$166,928,649.002026/06/30	非公開
CUSIP 04280A100Arrowhead Pharmaceuticals, Inc. — COM	0.82%	1,992,783	非公開	$162,431,742.002026/06/30	非公開
CUSIP 462222100Ionis Pharmaceuticals, Inc. — COM	0.82%	2,047,727	非公開	$162,364,274.002026/06/30	非公開
CUSIP 28036F105Edgewise Therapeutics, Inc. — COM	0.76%	3,701,719	非公開	$150,400,843.002026/06/30	非公開
CUSIP 76029N106Replimune Group, Inc. — COM	0.61%	11,045,336	非公開	$122,271,870.002026/06/30	非公開
CUSIP 67080M103Nurix Therapeutics, Inc. — COM	0.57%	4,658,556	非公開	$113,016,569.002026/06/30	非公開
CUSIP 86150R107Stoke Therapeutics, Inc. — COM	0.55%	3,336,697	非公開	$109,176,726.002026/06/30	非公開
CUSIP 61225M102Monte Rosa Therapeutics, Inc. — COM	0.53%	4,345,736	非公開	$105,166,811.002026/06/30	非公開
CUSIP N44445109Immatics N.V. — SHS	0.48%	9,508,565	非公開	$96,321,763.002026/06/30	非公開
CUSIP 24823R105Denali Therapeutics Inc. — COM	0.48%	3,734,336	非公開	$96,047,122.002026/06/30	非公開
CUSIP 22663K107Crinetics Pharmaceuticals, Inc. — COM	0.44%	2,351,465	非公開	$87,991,820.002026/06/30	非公開
CUSIP 252828108Dianthus Therapeutics, Inc. — COM	0.42%	852,164	非公開	$83,068,947.002026/06/30	非公開
CUSIP 86366E106Structure Therapeutics Inc. — SPONSORED ADS	0.39%	1,432,529	非公開	$76,883,831.002026/06/30	非公開
CUSIP 75383L102Rapport Therapeutics, Inc. — COM	0.32%	1,547,090	非公開	$64,467,240.002026/06/30	非公開
CUSIP 022307102Alumis Inc. — COM	0.28%	2,012,500	非公開	$56,631,750.002026/06/30	非公開
CUSIP 74065P101Prelude Therapeutics Inc. — COM	0.27%	10,123,824	非公開	$53,959,982.002026/06/30	非公開
CUSIP 75943R102Relay Therapeutics, Inc. — COM	0.27%	2,826,783	非公開	$52,889,110.002026/06/30	非公開
CUSIP 604749101Mirum Pharmaceuticals, Inc. — COM	0.26%	445,975	非公開	$52,210,293.002026/06/30	非公開
CUSIP 088786108Bicycle Therapeutics plc — SPONSORED ADS	0.23%	10,885,357	非公開	$46,153,914.002026/06/30	非公開
CUSIP 29337E102Enliven Therapeutics, Inc. — COM	0.23%	905,191	非公開	$45,938,443.002026/06/30	非公開
CUSIP 15117B202Celldex Therapeutics, Inc. — COM	0.22%	1,182,611	非公開	$44,004,955.002026/06/30	非公開
CUSIP 92790C104Viridian Therapeutics, Inc. — COM	0.22%	2,383,025	非公開	$43,776,169.002026/06/30	非公開
CUSIP 25056L103Design Therapeutics, Inc. — COM	0.19%	2,678,430	非公開	$38,756,882.002026/06/30	非公開
CUSIP 29384C108Entrada Therapeutics, Inc. — COM	0.19%	5,072,730	非公開	$37,335,293.002026/06/30	非公開
CUSIP 81728A207Faeth Therapeutics, Inc. — COM	0.16%	1,286,411	非公開	$32,160,275.002026/06/30	非公開
CUSIP 01021M104Aktis Oncology, Inc. — COM	0.16%	996,351	非公開	$32,112,393.002026/06/30	非公開
CUSIP 64135M105Neurogene Inc. — COM	0.16%	991,691	非公開	$31,188,682.002026/06/30	非公開
CUSIP 008064206Jade Biosciences, Inc. — COM	0.14%	1,230,426	非公開	$27,340,066.002026/06/30	非公開
CUSIP 877619106Taysha Gene Therapies, Inc. — COM SHS	0.14%	4,004,756	非公開	$27,272,388.002026/06/30	非公開
CUSIP 03969F109Arcus Biosciences, Inc. — COM	0.13%	844,816	非公開	$26,045,677.002026/06/30	非公開
CUSIP 254604101Disc Medicine, Inc. — COM	0.13%	349,657	非公開	$25,573,913.002026/06/30	非公開
CUSIP 00091E109Absci Corporation — COM	0.12%	2,134,803	非公開	$24,742,367.002026/06/30	非公開
CUSIP 370920100Generate Biomedicines, Inc. — COM SHS	0.12%	1,423,602	非公開	$24,016,166.002026/06/30	非公開
CUSIP 23306J309DBV Technologies S.A. — SPONSORED ADS	0.12%	1,461,425	非公開	$23,967,370.002026/06/30	非公開
CUSIP 98420N105Xenon Pharmaceuticals Inc. — COM	0.11%	370,208	非公開	$22,345,755.002026/06/30	非公開
CUSIP 878972108Tectonic Therapeutic, Inc. — COM	0.11%	607,788	非公開	$20,892,713.002026/06/30	非公開
CUSIP 157085101Cerus Corporation — COM	0.09%	6,395,431	非公開	$18,674,659.002026/06/30	非公開
CUSIP 23284F105CytomX Therapeutics, Inc. — COM	0.09%	4,975,826	非公開	$18,659,348.002026/06/30	非公開
CUSIP 26818M108Dyne Therapeutics, Inc. — COM	0.09%	813,449	非公開	$18,066,702.002026/06/30	非公開
CUSIP 23282W605Cytokinetics, Incorporated — COM	0.09%	211,267	非公開	$17,997,836.002026/06/30	非公開
CUSIP 98401F105Xencor, Inc. — COM	0.09%	1,102,106	非公開	$17,743,907.002026/06/30	非公開
CUSIP 829401108Sionna Therapeutics, Inc. — COM	0.09%	400,000	非公開	$17,596,000.002026/06/30	非公開
CUSIP 45826J105Intellia Therapeutics, Inc. — COM	0.08%	930,232	非公開	$15,739,525.002026/06/30	非公開
CUSIP 698955101Parabilis Medicines, Inc. — COM	0.07%	500,000	非公開	$13,685,000.002026/06/30	非公開
CUSIP 56565P103MapLight Therapeutics, Inc. — COM	0.07%	364,705	非公開	$13,071,027.002026/06/30	非公開
CUSIP 05348Y105Avalyn Pharma Inc. — COM SHS	0.06%	350,000	非公開	$11,522,000.002026/06/30	非公開
CUSIP 30054Y107Evommune, Inc. — COM SHS	0.06%	847,390	非公開	$11,261,813.002026/06/30	非公開
CUSIP 09075V102BioNTech SE — SPONSORED ADS	0.06%	119,743	非公開	$11,142,086.002026/06/30	非公開
CUSIP 87583X109Tango Therapeutics, Inc. — COM	0.05%	333,333	非公開	$10,419,990.002026/06/30	非公開
CUSIP 05338F306Avalo Therapeutics, Inc. — COM	0.05%	550,000	非公開	$10,164,000.002026/06/30	非公開
CUSIP 81749D107Sera Prognostics, Inc. — CLASS A COM	0.05%	5,498,170	非公開	$10,006,669.002026/06/30	非公開
CUSIP 92337C203Verastem, Inc. — COM	0.05%	2,499,338	非公開	$9,547,471.002026/06/30	非公開
CUSIP 786700104Sagimet Biosciences Inc. — COM SER A	0.04%	952,996	非公開	$7,366,659.002026/06/30	非公開
CUSIP 282564103Eikon Therapeutics, Inc. — COM	0.04%	555,555	非公開	$7,249,993.002026/06/30	非公開
CUSIP 50180M108LB Pharmaceuticals Inc. — COM SHS	0.03%	200,000	非公開	$6,491,000.002026/06/30	非公開
CUSIP 918385204vTv Therapeutics, Inc. — CL A	0.03%	148,314	非公開	$5,584,022.002026/06/30	非公開
CUSIP Y95308105Wave Life Sciences Ltd. — SHS	0.02%	822,638	非公開	$4,779,527.002026/06/30	非公開
CUSIP 74365U107Protara Therapeutics, Inc. — COM STK	0.02%	971,614	非公開	$3,711,565.002026/06/30	非公開
CUSIP 89854M101TScan Therapeutics, Inc. — COM	0.01%	2,784,792	非公開	$2,729,375.002026/06/30	非公開
CUSIP 45257U108Immunome, Inc. — COM	0.01%	55,306	非公開	$1,171,934.002026/06/30	非公開
CUSIP 83086J200Skye Bioscience, Inc. — COM	0.01%	1,575,243	非公開	$1,092,116.002026/06/30	非公開
CUSIP 799566104Sana Biotechnology, Inc. — COM	0.01%	310,483	非公開	$1,083,586.002026/06/30	非公開
CUSIP 01626L204Aligos Therapeutics, Inc. — COM	0%	83,055	非公開	$479,227.002026/06/30	非公開
CUSIP 90240B106Tyra Biosciences, Inc. — COM	0%	10,607	非公開	$338,788.002026/06/30	非公開
CUSIP 86889P117Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1) — W EXP 8/11/2026	0%	833,333	非公開	$13,750.002026/06/30	非公開

ポートフォリオの一部のみ公開

銘柄別損益には、公開された取得原価と同じ通貨での日付付き評価額が必要です。配当や実現益を含まない含み損益です。未公開の数値は推測しません。

追跡戦略

Biotech All-Star Tracker

2026/10/25時点

出典 ↗

追跡戦略の保有銘柄と顧客ポートフォリオの収益率です。本人の保有銘柄や利益を示すものではありません。

Biotech All-Star Tracker · 2026/10/25時点
銘柄	構成比	含み損益
KODKodiak Sciences Inc Common Stock	12.1%	非公開
ONCBeOne Medicines Ltd. American Depositary Shares	6.2%	非公開
ROIVRoivant Sciences Ltd. Common Shares	5.8%	非公開

ポートフォリオの一部のみ公開 · ほか16銘柄は非公開 (75.9%)

公開されたポートフォリオ収益率

2026/10/23時点 · 開始日：2026/08/20

直近1か月: +1.34%
開始来: -11.05%

収益率の算出方法

The performance data presented reflects the aggregated results of actual client portfolios managed by the Registered Investment Adviser (RIA), based on the trading activity in the securities contained in the relevant portfolio over the specified period. If fewer than 10 clients are invested in the portfolio, the data represents the aggregate performance of all clients following this strategy. Performance figures are shown net of advisory fees, calculated using the applicable subscription fee and an assumed $50,000 account size. Because subscription fees are flat rather than asset-based, accounts smaller than $50,000 would experience a higher effective fee percentage and lower net performance, while larger accounts would experience a lower effective fee percentage. Actual investor outcomes can vary due to factors like brokerage support for fractional shares, account size, trade timing, fees, and taxes, and past performance should not be interpreted as a guarantee of future results or typical of all portfolios.

Felix Baker

人生の局面1

個人の保有銘柄と損益

個人の取引と損益

Felix Baker

人生の局面1

個人の保有銘柄と損益

個人の取引と損益

Baker Bros. Advisors — SEC 13F

Biotech All-Star Tracker

公開されたポートフォリオ収益率

仕事と実績8

歴任した役職1

取り組み1

作品5

創業した企業1

出典5

Felix Baker

人生の局面1

個人の保有銘柄と損益

個人の取引と損益

ファンド保有銘柄と追跡戦略

Felix Baker

人生の局面1

個人の保有銘柄と損益

個人の取引と損益

ファンド保有銘柄と追跡戦略

公開されたポートフォリオ収益率

仕事と実績8

歴任した役職1

取り組み1

作品5

創業した企業1

出典5